Administer 1-2 mg of benztropine intravenously or intramuscularly for acute dystonic reactions. Observe the patient closely for at least 30 minutes following administration. If symptoms persist or worsen, repeat the dose, but consider alternative anticholinergic agents like diphenhydramine (25-50 mg IV or IM).
For severe extrapyramidal symptoms (EPS), consider using a lower dose of haloperidol or switching to another antipsychotic medication with a lower EPS risk profile. Consult with a specialist for guidance on appropriate medication changes.
Neuroleptic Malignant Syndrome (NMS) is a rare but serious complication. Monitor patients closely for symptoms such as high fever, muscle rigidity, altered mental status, and autonomic instability. If NMS is suspected, discontinue haloperidol immediately and initiate supportive care, including fluid management and temperature control. Rapid consultation with an intensivist is crucial.
Hypotension can occur, especially with rapid intravenous administration. Administer slowly and monitor blood pressure. If hypotension develops, consider fluid resuscitation.
Cardiac arrhythmias are a possibility, particularly in patients with pre-existing cardiac conditions. Close cardiac monitoring is recommended, especially during initial administration.
For any unusual or concerning adverse effects, promptly seek medical attention. Document all medication administration, vital signs, and patient responses meticulously.
